Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019.
Neurol Clin Pract
; 11(1): 49-56, 2021 Feb.
Article
en En
| MEDLINE
| ID: mdl-33968472
ABSTRACT
PURPOSE OF REVIEW To provide an evidence-based approach to the use of therapies that are prescribed to improve the natural history of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)-a rare disease. RECENT FINDINGS:
All 41 articles on the clinical outcome of disease-modifying therapy for HAM/TSP were included in a systematic review by members of the International Retrovirology Association; we report here the consensus assessment and recommendations. The quality of available evidence is low, based for the most part on observational studies, with only 1 double-masked placebo-controlled randomized trial.SUMMARY:
There is evidence to support the use of both high-dose pulsed methyl prednisolone for induction and low-dose (5 mg) oral prednisolone as maintenance therapy for progressive disease. There is no evidence to support the use of antiretroviral therapy. There is insufficient evidence to support the use of interferon-α as a first-line therapy.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Guideline
/
Observational_studies
/
Systematic_reviews
Idioma:
En
Revista:
Neurol Clin Pract
Año:
2021
Tipo del documento:
Article